{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-068730","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.150360+00:00","generated_at":"2026-06-14T05:39:22.732621+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"CytoSorbents shareholders elect directors, approve say-on-pay, ratify auditor at 2023 annual meeting","bullets":["All five director nominees elected with at least 18.6M votes for; no dissident candidates.","Advisory approval of named executive officer compensation passed: 14.1M for, 2.8M against, 4.0M abstain.","Ratification of WithumSmith+Brown, PC as auditor for FY 2023: 29.4M for, 268k against, 145k abstain.","Quorum of 29.8M shares (67.8% of outstanding) represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-068730","json":"https://secwatch.observer/filing/0001104659-23-068730.json","markdown":"https://secwatch.observer/filing/0001104659-23-068730.md","text":"https://secwatch.observer/filing/0001104659-23-068730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923068730/0001104659-23-068730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923068730/tm2317973d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:39:22.732621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"124649e92a6fa5b23ee6d82cd5f85443249ee1b7","claim":"Cytosorbents Corp shareholders approved Election of five directors to serve until the Company's 2024 Annual Meeting of Stockholders, or until their respective successors shall have been duly elected and qualified at the 2023-06-06 meeting.","evidence_excerpt":"Proposal No. 1 — Election of Directors The vote with respect to the election of directors was as follows: Nominees For Against Abstain Broker Non-Votes Dr. Phillip P. Chan 20,039,568 790,050 71,592 8,925,916 Dr. Edward R. Jones 20,176,235 653,457 71,518 8,925,916 Michael Bator 18,628,159 2,200,221 72,830 8,925,916 Alan D. Sobel 20,076,869 749,935 74,406 8,925,916 Jiny Kim 20,213,793 554,746 132,671 8,925,916","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923068730/0001104659-23-068730-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"},{"claim_id":"64b22a787bf5bfb2d96e090d6731773db52f4af8","claim":"Cytosorbents Corp shareholders approved Ratification of the appointment of WithumSmith+Brown, PC, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-06 meeting.","evidence_excerpt":"Proposal No. 3 — Ratification of the Appointment of Independent Registered Public Accounting Firm The vote with respect to the ratification of the appointment of WithumSmith+Brown, PC, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: For Against Abstain 29,413,721 268,190 145,215","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923068730/0001104659-23-068730-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"},{"claim_id":"aed3b376ef7b595b0ebfb684a84937fb24466e22","claim":"Cytosorbents Corp shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers, disclosed pursuant to Item 402 of Regulation S-K at the 2023-06-06 meeting.","evidence_excerpt":"Proposal No. 2 — Approval of the Compensation of the Company’s Named Executive Officers The vote with respect to the approval of, on an advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K was as follows : For Against Abstain Broker Non-Votes 14,146,730 2,774,611 3,979,869 8,925,916","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923068730/0001104659-23-068730-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}